Double Coated Tablets of Nimesulide for Colon Targeting
DOI:
https://doi.org/10.37285/ijpsn.2010.3.2.14Abstract
The present study was aimed at developing oral colon targeted drug delivery system for Nimesulide utilizing recently designed and patented system called CODESTM, which consisted of a lactulose containing core overcoated with both Eudragit E and Eudragit L designed to rapidly disintegrate in the colon, in order to give a new life for an existing banned drug. CODESTM tablets were prepared by tabletting Nimesulide and lactulose, followed with film coating of Eudragit. The prepared tablets were evaluated on the basis of in vitro dissolution study and in vivo disintegration study was performed by gamma scintigraphic evaluation in rats. The onset of Nimesulide release was found to dependent on the coating level of Eudragit E, and at Eudragit E coating level of 8% (coating weight gain), the onset of in vitro drug release was found to be optimum. When the same was subjected on scintigraphic evaluation for in vivo disintegration study, there was a reasonable agreement between the in vitro/in vivo data. It is concluded that Nimesulide can be targeted to hindgut by a novel approach of CODESTM.
Downloads
Metrics
Keywords:
Nimesulide, NSAIDs, Colorectal Cancer, Colon Specific Delivery, Polymethacrylate polymers, Gamma Scintigraphy.
Downloads
Published
How to Cite
Issue
Section
References
Angulo, A.M.G., Fuloria, J., Prakash, O., 2002. Cyclooxygenase 2 inhibitors and colon cancer. Ochsner J., 4, 176-179.
Eaden, J.A., Abrams, K.R., Mayberry, J.F., 2001. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535.
Ekbom, A., Helmick, C., Zack, M., Adami, HO., 1990. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med., 323, 1228-1233.
Fukutake, M., Nakatsugi, S., Isoi, T., Takahashi, M., Ohta, T., Mamiya, S., Taniguchi, Y., Sato, H., Fukuda, K., Sugimura, T., Wakabayashi, K., 1998. Suppressive effects of nimesulide, a selective inhibitor of Cyclooxygenase-2, on azoxymethane induced colon carcinogenesis in mice. Carcinogenesis, 19, 1939-1942.
Giovannucci, E., Egan, K.M., Hunter, D.J., Stampfer, M.J., Colditz, G.A., Willett, W.C., Speizer, F.E., 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333, 609-614.
Haruta, S., Kawai, K., Jinnouchi, S., Ogawara, K.I., Higaki, K.. 2003. Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy. J. Pharm. Sci. 90, 464-472.
Katsuma, M., Watanabe, S., Kawai, H., Takemura, S., Masuda, Y., Fukui, M., 2002. Studies on lactulose formulations for colon-specific drug delivery. Int. J. Pharm., 249, 33-43.
Katsuma, M., Watanabe, S., Takemura, S., Sako, K., Sawada, T., Masuda, Y., Nakamura, K., Fukui, M., Connor, A.L., Wilding, I.R., 2004. Scintigraphic evaluation of a novel colon-targeted delivery system (CODESTM) in healthy volunteers. J. Pharm. Sci., 93, 1287-1299.
Li, J., Yang, L., Ferguson, S.M., Hudson, T.J., Watanabe, S., Katsuma, M., Fix, J.A., 2002. In Vitro Evaluation of Dissolution Behavior for a Colon-Specific Drug Delivery System (CODES™) in Multi-pH Media Using United States Pharmacopeia Apparatus II and III. AAPS PharmSciTech, 3, article 33.
Reddy, B.S., Hirose, Y., Lubet, R., 2000. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res., 60, 293–297.
Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L.K., Levin, B., Godio, L., Patterson, S., Bigas, M.A.R., Jester, S.L., King, K.L., Schumacher, M., Abbruzzese, J., DuBois, R.N., Hittelman, W.N., Zimmerman, S., Sherman, J.W., Kelloff, G., 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T., Yamamoto, A., Muranishi, S., 1997. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J. Pharm. Sci., 86, 1016-1021.
Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T., Yamamoto, A., Muranishi, S., 1997. Chitosan capsules for colon-specific drug delivery: Improvement of insulin absorption from the rat colon. J. Pharm. Sci., 86, 1016-1021.
Weitzman, S.A., Gordon, L.I., 1990. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood, 76, 655-663.
Yang, L., Chu, J.S., Fix, J.A., 2002. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm., 235, 1-15.
